| 摘要 |
<p>A process for the manufacture of an influenza vaccine comprises cultivating an influenza virus, pathogenic towards the epithelium of the respiratory tract of a mammal, in the pulmonary tissue of a mammal until its pathogenicity towards said epithelium is not modified by being passed through an incubated fertile hen's egg, then allowing a resulting virus to multiply in an incubated fertile hen's egg and preparing the vaccine from the virus-containing allantoic liquid so obtained, and, if desired, adding an adjuvant. The vaccine may be inactivated by formaldehyde, hydroxylamine, b -propiolactam or ultra-violet radiation. The adjuvant may be alum, aluminium phosphate or hydroxide, or incomplete Freund's adjuvant. Influenza virus types A, B and C and their strains, e.g. A/PR8, A1/FM1, A1/Ann Arbor, A2/Asia, A2/Japan, B/Stockholm, B/Johannesburg, B/Maryland, B/Lee or C/Taylor may be used. An example describes influenza vaccines comprising influenza viruses of the A2/Asia strain Singapore cultivated by means of 424 passages through pulmonary tissue of mice and subsequently 33 passages through incubated eggs.</p> |
